Helsinn Healthcare Archives

Home / Posts tagged Helsinn Healthcare

Taiho Pharmaceutical Obtains Approval to Manufacture and Market NK1 Receptor Antagonist Arokaris® I.V. Infusion 235mg in Japan

Tokyo, Japan, and Lugano, Switzerland March 28 (Korea Bizwire) - Taiho Pharmaceutical Co., Ltd. (hereinafter “Taiho”) and Helsinn Group (hereinafter “Helsinn”), announced today that Taiho has been granted approval from the Japanese Ministry of Health, Labour and Welfare to manufacture and market the NK1 receptor antagonist antiemetic drug “Arokaris® I.V. Infusion 235mg” (generic name: fosnetupitant chloride hydrochloride) for gastrointestinal symptoms (nausea and vomiting, [...]

Helsinn and Xediton Sign Exclusive License and Distribution Agreement for TRUSELTIQ™ (infigratinib) in Canada

Lugano, Switzerland, and Mississauga, Ontario, Dec. 20 (Korea Bizwire) – Helsinn Group (Helsinn), a Swiss Biopharmaceutical Group with an innovative R&D pipeline in cancer supportive care and oncology therapeutics, strategically investing in a fully integrated targeted therapy structure to develop, manufacture and commercialize small molecules in precision medicine with higher market potential, and Xediton Pharmaceuticals Inc. (Xediton), a Canadian [...]

Helsinn Achieves Carbon Neutrality

Lugano, Switzerland, Dec. 6 (Korea Bizwire) - Helsinn Group (“Helsinn”), a fully integrated, global biopharma company with a diversified pipeline of innovative oncology assets and strong track-record of commercial execution, today announces that it has achieved carbon neutrality for the first time. Since 2012, Helsinn has been committed to becoming more sustainable. Our environmental performance has improved steadily through [...]

Helsinn Announces First Patient Dosed in Phase 1/2 Study of TAS0953/HM06 in Patients with Advanced Solid Tumors with RET Gene Abnormalities

Lugano, Switzerland, Jan. 12 (Korea Bizwire)– Helsinn, a Swiss pharmaceutical group focused on building quality cancer care and rare disease products, today announces the first patient has been dosed in a Phase 1/2 Study of TAS0953/HM06 in Patients with Advanced Solid Tumors with RET Gene Abnormalities. TAS0953/HM06 is an investigational oral treatment which inhibits several [...]

3B Future Health Fund Announces New Investment in iOnctura

MONACO, PRINCIPALITY OF MONACO, July 14 (Korea Bizwire) – 3B Future Health Fund, previously known as Helsinn Investment Fund S.A., SICAR, today announces that it has invested in iOnctura SA, a clinical stage biopharmaceutical company developing a pipeline of next generation molecules targeting cancer and fibrosis. iOnctura has raised an additional EUR 5.1 million bringing iOnctura’s [...]

Helsinn Group and MEI Pharma Discontinue the Phase 3 Study with Pracinostat in AML After Completing Interim Analysis

Lugano, Switzerland and San Diego, USA, July 2 (Korea Bizwire) – Helsinn, a Swiss pharmaceutical group focused on building quality cancer care and rare diseases products, and MEI Pharma, Inc. (Nasdaq: MEIP), a late-stage pharmaceutical company focused on advancing potential new therapies for cancer, today announce that an interim futility analysis of the ongoing Phase 3 [...]

New Insights on Mechlorethamine/Chlormethine Gel Presented at 4th World Congress of Cutaneous Lymphomas

Lugano, Switzerland, Feb. 14 (Korea Bizwire) – Helsinn, the Swiss pharmaceutical group focused on building quality cancer care products, today announces that scientific abstracts have been accepted for oral presentation and one abstract for poster presentation at the World Congress of Cutaneous Lymphomas (WCCL) taking place from 12-14th February 2020 in Barcelona, Spain. The first oral presentation, [...]

Lyfebulb and Helsinn Announce the Winners of the Third Annual Lyfebulb-Helsinn Cancer Innovation Summit & Award

MONACO, PRINCIPALITY OF MONACO, AND NEW YORK, NY, USA, Jan. 31 (Korea Bizwire) - Lyfebulb, a patient empowerment platform that connects patients with industry to support user-driven innovation toward solutions in chronic disease, and Helsinn, a Swiss pharmaceutical group focused on building quality cancer care, announce that Russell LaMontagne of Boston Immune Technologies and Therapeutics was chosen [...]

Conquer Cancer Foundation/Anna Braglia Endowed Young Investigator Award (YIA) in Cancer Supportive Care, Supported by Helsinn, Awarded to Dr. Allison Barz Leahy, MD, University of Pennsylvania

Lugano, Switzerland, Jun. 1 (Korea Bizwire) – Helsinn, the Swiss pharmaceutical group focused on building quality cancer care products, in conjunction with the Conquer Cancer Foundation of the American Society of Clinical Oncology (ASCO), today announces Allison Barz Leahy, MD, University of Pennsylvania, as the recipient of the Anna Braglia Endowed Young Investigator Award in [...]

Helsinn Group and MEI Pharma Announce Upcoming Presentation at ASCO 2018 on the Design of the Phase III PRIMULA Study of Pracinostat in Combination with Azacitidine for the Treatment of Acute Myeloid Leukemia (AML)

Lugano, Switzerland, May 30 (Korea Bizwire) – Helsinn, a Swiss pharmaceutical group focused on building quality cancer care products, and MEI Pharma, Inc. (Nasdaq: MEIP), a pharmaceutical company focused on leveraging its extensive development and oncology expertise to identify and advance new therapies for cancer, today announce that the PRIMULA study design will be presented at [...]